

Measurement of uracil in plasma and serum samples by LC-MS/MS

Dan Blake and Melissa McGuinness
SCIEX, UK

Researchers studying the toxicity of widely used fluoropyrimidine drugs, such as capecitabine and 5-fluorouracil, are interested in the analysis of the nucleobase uracil in biological matrices because, in theory, uracil levels may correspond to the degree of drug toxicity experienced by patients. Research has also suggested that fluoropyrimidine toxicity may be linked to genetic variance and research is ongoing to investigate whether uracil levels mirror this genetic stratification.

The analysis of very small molecules, including nucleobases such as uracil, presents unique challenges that must be overcome. Selectivity can be an issue, leading to poor sensitivity and the need for extensive sample preparation. LC-MS/MS, however, is one technique that can address these challenges. However, some molecules, particularly very small ones such as uracil, can present chromatographic and selectivity challenges for LC-MS/MS approaches, and appropriate methods need to be developed to fully leverage the potential of LC-MS/MS in terms of ease of use, simple sample preparation, sensitivity, linearity and reproducibility.



Key features of the SCIEX Triple Quad 6500+ system for the analysis of uracil

- High sensitivity was achieved, demonstrated by the 0.5 ng/mL limit of quantification (LLOQ) for uracil in a small volume of plasma/serum (Figure 1)
- Strong quantitative performance was demonstrated by linear and reproducible results across all concentrations.
- Fast run times were achieved due to simplified chromatography, small sample volumes and straightforward extraction procedures

Materials and Methods

Sample preparation: A 100 μ L sample of plasma/serum was precipitated with acetonitrile:methanol, and the supernatant was diluted with water:formic acid. 25 μ L of the supernatant was injected onto the LC-MS/MS system.

Chromatography: Chromatographic separation was achieved on a Phenomenex Kinetex PS C18 (2.6 μ m, 4.6 x 100mm) column. Mobile phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic acid in methanol. The total run time was 5 minutes, at 97% mobile phase A. The flow rate was 0.45 mL/min.




Figure 1: Detection of uracil in bovine serum albumin (BSA) matrix. Chromatogram of uracil in BSA at the LLOQ (0.5 ng/mL) versus a blank extract. The signal-to-noise ratio of the uracil sample was > 10:1.

Mass spectrometry: The SCIEX Triple Quad 6500+ system, operated with Analyst software 1.7.1, was used to analyze the samples. MRM parameters were optimized by infusion. The IonDrive Turbo V ion source was operated in electrospray mode (ESI).

Data processing: A qualitative data review was performed using the Explorer module in SCIEX OS software. A quantitative analysis was performed using the Analytics module in SCIEX OS software.

Results

The LC-MS/MS methodology was developed using careful sample preparation and isocratic chromatography to maximize sensitivity, linearity and reproducibility.

Sensitivity: The limit of quantification (LLOQ) for uracil in bovine serum albumin (BSA) was 0.5 ng/mL. Figure 2 shows the uracil peak at 2.806 min for a 0.5 ng/ml (LLOQ) in BSA sample. The blue bars provide a visual indication of the signal-to-noise ratio, which is greater than 10:1.

Linearity: Linearity was assessed over a concentration range of 0.5 to 200 ng/mL uracil in BSA, with 6 replicates at each concentration. Linear regression was used, based on peak areas and a 1/x weighting. The r^2 value was greater than 0.999, indicating strong linearity in this concentration range. The resulting calibration curve is shown in Figure 3.

Reproducibility and robustness: To assess reproducibility and robustness, 6 replicates of calibration standards from 0.5 to 200 ng/mL uracil in BSA were analyzed. A summary of the results obtained is shown in Table 1. The results were highly reproducible, as the %CV was less than 8.5 at all concentrations tested.




Figure 2: Sensitivity of uracil in BSA matrix. The extracted ion chromatogram of uracil at 0.5 ng/mL in BSA had a signal-to-noise ratio (based on 3SD of the noise) >10:1.

Table 1: Reproducibility (%CV) and accuracy of the calibration curve for uracil in BSA. The concentration range of 0.5 to 200 ng/mL uracil in BSA was run with 6 replicates at each concentration.

Concentration (ng/mL)	%CV	Accuracy
0.50	8.33	103.46
1.00	3.24	95.04
2.50	5.13	100.10
5.00	1.19	99.79
10.00	5.67	104.82
15.00	1.47	98.62
20.00	2.47	100.52
25.00	2.29	98.09
50.00	2.32	97.29
75.00	2.23	104.66
100.00	1.77	97.62
150.00	1.13	99.25
200.00	1.00	100.76

Sample type comparison

Using the established and described method, a number of anonymized research samples were analyzed in both EDTA (plasma) and serum (Tables 2 and 3).

It was clear from the results that sample type was responsible for a significant difference in the uracil concentrations reported. For example, for sample number 24, the concentration of uracil in EDTA (plasma) was 23.54 ng/mL versus 8.66 ng/mL in the serum sample.




Figure 3: Linear calibration curve. Uracil was spiked into BSA at concentrations ranging from 0.5 to 200ng/mL. Each concentration point was run with 6 replicates. The resulting calibration curve was highly linear, with $r^2 > 0.999$.

Table 2. EDTA (plasma) samples.

Sample number	Concentration (ng/mL)	Sample number	Concentration (ng/mL)
1	51.38	20	38.36
2	45.74	21	45.91
3	43.09	22	47.48
4	25.33	23	50.43
5	23.43	24	23.54
6	38.31	25	23.02
7	50.18	26	57.00
8	89.55	27	156.13
9	34.80	28	27.02
10	42.76	29	71.01
11	36.65	30	88.48
12	47.73	37	46.69
13	20.22	32	17.46
14	48.39	33	14.69
15	44.15	34	51.15
16	31.09	35	46.87
17	38.58	36	47.17
18	57.14	37	44.86
19	39.03		

Table 3. Serum samples.

Sample number	Concentration (ng/mL)	Sample number	Concentration (ng/mL)
1	15.09	20	21.12
2	9.51	21	35.19
3	20.64	22	29.37
4	7.58	23	18.6
5	20.42	24	8.66
6	10.67	25	9.6
7	30.54	26	18.52
8	17.06	27	63.47
9	8.75	28	13.98
10	15.76	29	13.26
11	9.65	30	88.28
12	38.38	31	23.14
13	25.43	32	8.71
14	29.24	33	17.94
15	11.4	34	18.28
16	13.5	35	8.27
17	25.65	36	25.3
18	26.83	37	17.33
19	30.26		

Conclusions

Methods were developed for the quantitative analysis of uracil in plasma and serum matrices using isocratic chromatography. A simple and automatable sample preparation method was developed using a protein precipitation from a 100 μ L sample volume, with 25 μ L injected onto the LC-MS/MS system. The LC-MS/MS methodology provided excellent sensitivity, linearity and reproducibility.

Preliminary results using LC-MS/MS show significant differences in uracil levels quantified from EDTA (plasma) and serum in the same research sample. Further studies on larger cohorts of samples are necessary to determine the best strategy or appropriate sample type for this analysis.

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2021 DH Tech. Dev. Pte. Ltd. RUO-MKT-02-14122-A.



Headquarters
 500 Old Connecticut Path | Framingham, MA 01701 USA
 Phone 508-383-7700
sciex.com

International Sales
 For our office locations please call the division
 headquarters or refer to our website at
sciex.com/offices